Robotic Approach to Urothelial Cancer of the Kidney Proves to Be Beneficial for Patients
CHICAGO (April 26, 2009) – Robotic trained surgeons at Fox Chase Cancer Center in Philadelphia presented a new and novel approach to surgically treat urothelial cancer (in the lining of the bladder or kidney) today at the American Urological Association's Annual Meeting. Using da Vinci® robot-assisted technology, urologic cancer surgeons perform complicated urologic cases using minimally invasive surgery.
Standard treatment for ureteral cancer is surgical resection of the tumor, called a distal ureterectomy, or removal of the entire kidney, called a nephro-ureterectomy. Depending on the experience of the surgeon, this procedure can be performed using open surgery, while others may elect a laparoscopic approach. In either instance, the surgeon’s experience is vital for preserving function of the kidney.
“A minimally invasive approach to this procedure is challenging for even the most experienced laparoscopist. This is due to the technical challenge of re-implanting the ureter into the bladder,” says Rosalia Viterbo, MD, robotic surgeon at Fox Chase and co-author on the study. “Robotic assistance can make a minimally invasive approach more technically feasible.”
In this video abstract, Fox Chase urologic cancer surgeons, Viterbo and her colleague David Y.T. Chen, MD, demonstrate the four-arm technique for robot assisted distal ureterectomy.
In the video, Viterbo is shown performing the robotic distal ureterectomy on a 73-year-old man with a distal left ureteral tumor. She explains, “The patient presented with stage 3 chronic kidney disease, so a nephron-sparing approach was taken to preserve kidney function. During the surgery, the four robotic arms and two assistant ports were successfully positioned in a manner similar to robot assisted radical prostatectomy.”
This approach resulted in the usual benefits associated with minimally invasive surgeries, such as less bleeding and scarring, shorter hospital stay, faster recovery and return to normal activity and with his kidney function preserved.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).